We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix
Product News

Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix

Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix
Product News

Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avacta Group plc has announced that a BAMS™ (bead-assisted mass spectrometry) diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test.

The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus recently developed by Avacta to capture the virus spike protein from the sample for rapid detection by mass spectrometry.

A prototype assay has now been developed and evaluated by Adeptrix using model samples containing the coronavirus spike protein. The unique method breaks up the spike protein captured from the samples by Affimer coated beads and is able to identify fragments of the spike protein using mass spectrometry, at concentrations in the range found in patient samples generated from standard throat swabs.

The combination of the selectivity of the Affimer reagents used to capture the virus spike protein with the precision and accuracy of mass spectrometry detection provides for a very high degree of specificity in the assay.

The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimize the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.

Advertisement